Antibody Technology Research Center

Overview
No Image

The goal of the Antibody Technology Resource Center (ATRC) is to develop high quality recombinant antibodies (rAbs) to challenging high-value protein targets. Antibodies (Abs) are essential reagents. The generation of widely available, renewable, validated and standardized sets of rAbs will significantly accelerate studies of protein function.

We are focusing on generating rAbs to secreted extracellular and membrane proteins and protein post-translational modifications (PTMs) for the following reasons:
  • they comprise 20-40% of all proteins;
  • they have proven challenging to either express, purify and/or successfully use for Ab generation;
  • their biomedical importance as research tools and drugs.
The ATRC has three Technology Research and Development (TR&D) projects that will develop novel high throughput antigen and antibody generation technology to generate rAbs.

TR&D 1. Develop technology to generate rAbs to secreted extracellular, single pass and multipass membrane proteins using yeast displayed antigens, cell lines and phage antibody libraries led by James D. Marks;

No Image


TR&D 2. Develop technology to generate conformationally-specific rAbs to proteases using purified protein, immune and non-immune antibody libraries and deep sequencing, led by Charles Craik;

No Image


TR&D 3. Develop technology to generate rAbs to phosphorylated peptides representing portions of signaling proteins from designed phage libraries, led by James Wells.

No Image


Driving Biomedical Projects inform target selection and use rAbs for structural and functional assays. These ongoing NIH-funded projects will benefit from ready access to high quality rAbs. Abs will be widely disseminated to investigators to the scientific community.

The ATRC provides training in the antibody generation technologies.

The ATRC disseminates methods, plasmids containing antibody vectors, antibody-expressing cell lines and antibody reagents.